$0.22 2.2%
BNGO Stock Price vs. AI Score
Data gathered: November 23

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Bionano Genomics (BNGO)

Analysis generated March 8, 2024. Powered by Chat GPT.

Bionano Genomics is a biotechnology company focused on genome analysis space. They specialize in optical genome mapping (OGM), which is an innovative approach to the analysis of genomic structure. OGM technology, provided through their platform Saphyr, allows researchers and clinicians to accelerate the discovery of diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The company is making efforts to revolutionize the standard of care in various fields of genetic health and cancer, as well as to enhance our understanding of genome biology.

Read full AI stock Analysis

Stock Alerts - Bionano Genomics (BNGO)

company logo Bionano Genomics | November 20
Price is down by -6.5% in the last 24h.
company logo Bionano Genomics | November 18
Price is down by -5.3% in the last 24h.
company logo Bionano Genomics | November 15
Price is down by -5.9% in the last 24h.
company logo Bionano Genomics | November 14
Price is down by -12.4% in the last 24h.

About Bionano Genomics

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.


Bionano Genomics
Price $0.22
Target Price Sign up
Volume 2,920,000
Market Cap $22M
Year Range $0.21 - $1.15
Dividend Yield 0%
PE Ratio 0.03
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '246.1M43M-37M-44M-44M0.000
Q2 '2412M17M-5M-16M-17M-0.220
Q1 '248.4M26M-18M-31M-31M-0.510
Q4 '235.9M31M-25M-44M-32M-0.959
Q3 '239.2M109M-99M-113M-112M-1.000

Insider Transactions View All

Mamuszka Hannah filed to buy 65,789 shares at $0.8.
June 14 '23
Holmlin R. Erik filed to buy 806,474 shares at $0.6.
May 16 '23
Stewart Christopher P. filed to buy 281,373 shares at $0.7.
May 16 '23
BARKER DAVID L filed to buy 13,894 shares at $1.6.
May 18 '22

What is the Market Cap of Bionano Genomics?

The Market Cap of Bionano Genomics is $22M.

What is Bionano Genomics' PE Ratio?

As of today, Bionano Genomics' PE (Price to Earnings) ratio is 0.03.

What is the current stock price of Bionano Genomics?

Currently, the price of one share of Bionano Genomics stock is $0.22.

How can I analyze the BNGO stock price chart for investment decisions?

The BNGO stock price chart above provides a comprehensive visual representation of Bionano Genomics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bionano Genomics shares. Our platform offers an up-to-date BNGO stock price chart, along with technical data analysis and alternative data insights.

Does BNGO offer dividends to its shareholders?

As of our latest update, Bionano Genomics (BNGO) does not offer dividends to its shareholders. Investors interested in Bionano Genomics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Bionano Genomics?

Some of the similar stocks of Bionano Genomics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.